Please login to the form below

Not currently logged in
Email:
Password:

insulin aspart

This page shows the latest insulin aspart news and features for those working in and with pharma, biotech and healthcare.

Gilead's hepatitis B virus treatment set for European approval

Gilead's hepatitis B virus treatment set for European approval

The dual-therapy works to reduce high blood glucose while enhancing glucose-dependent insulin secretion and reducing glucagon release. ... Meanwhile, Novo Nordisk looks set to add Fiasp (insulin aspart) to its diabetes drug stable, as the fast-acting

Latest news

  • Novo Nordisk's Tresiba gaining ground in basal insulin market Novo Nordisk's Tresiba gaining ground in basal insulin market

    Novo Nordisk's Tresiba gaining ground in basal insulin market. Delivers $216m this year despite ICER's report of insufficient data to favour the drug over Sanofi's Lantus. ... Nevertheless, the strong sales performance for Tresiba and other new insulin

  • Tresiba safer than insulin glargine, says Novo Nordisk Tresiba safer than insulin glargine, says Novo Nordisk

    Tresiba safer than insulin glargine, says Novo Nordisk. Trial compares its basal insulin with Sanofi's Lantus. ... Last October however the Danish drugmaker finally won US approval for Tresiba and combination product Ryzodeg (insulin degludec and insulin

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    Novo Nordisk finally bags insulin degludec approval in US. Aims to get Tresiba and Ryzodeg back on course . ... Long-acting basal insulin Tresiba (insulin degludec) and combination drug Ryzodeg (insulin degludec and insulin aspart) will now be able to

  • Novo brings Xultophy to third European market Novo brings Xultophy to third European market

    Novo Nordisk has launched its diabetes drug Xultophy (insulin degludec and liraglutide) in the UK, following its arrival earlier this year in Germany and Switzerland. ... US regulators dealt the company a major blow in February 2013 when marketing

  • FDA starts review of Novo's refiled diabetes pair FDA starts review of Novo's refiled diabetes pair

    The US FDA has started a fresh review of Novo Nordisk's long-acting insulin therapies Tresiba and Ryzodeg, which it turned down two years ago. ... Tresiba (insulin degludec) and combination product Ryzodeg (insulin degludec and insulin aspart) were

More from news
Approximately 3 fully matching, plus 27 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics